{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969341",
  "id": "02969341",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250715",
  "time": "0926",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250715/pdf/06lt23fwr9kjz3.pdf",
  "summary": "### Key Material Information Summary (Clinical Trial Update Announcement):  \n\n- **FDA Regulatory Update**: No issues identified in FDA meeting; greenlights **IND submission for Phase 2 trial** of MagSense\u00ae HER2 Breast Cancer imaging agent. IND filing expected **Q3 2025**.  \n- **Manufacturing Progress**: MagSense\u00ae HER2 agent production **on track for completion in Q3 2025**, aligning with trial timeline.  \n- **Principal Investigator Appointment**: Dr. William Dooley (renowned surgical oncologist) to lead Phase 2 multi-site study, reinforcing trial credibility.  \n\n*No capital markets or trading-specific actions (e.g., raising, halt) disclosed.*",
  "usage": {
    "prompt_tokens": 1508,
    "completion_tokens": 141,
    "total_tokens": 1649,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-14T23:43:21.280614"
}